It is becoming increasingly difficult to have a conversation about weight
and metabolic health without GLP-1 medications entering the room.
Semaglutide and tirzepatide have changed obesity medicine remarkably
quickly. For many women who have spent years battling hunger, weight
regain and the familiar advice to simply “eat less and move more”,
these medications can be transformative.
We know they work. The more interesting question now is how we use them
well and, particularly when treating women, that means paying attention
to the person taking the medication rather than simply the weight she
is losing.
Women are not simply smaller versions of men. This seems an obvious
statement, but historically medical research has not always reflected
it. We are learning more about differences in how disease develops and
presents in women, and about the significance of conditions and life
events that are unique to women or affect them disproportionately.
PMOS, endometriosis, PMDD, pregnancy, gestational diabetes, perimenopause
and menopause should not necessarily be viewed as separate episodes
in a woman’s medical history. They form part of a much bigger picture
of her health across the life course.
This matters when we prescribe GLP-1 medications.
A young woman with PMOS and insulin resistance, a woman struggling
with weight and metabolic change during perimenopause, and a woman
in her late 60s concerned about osteoporosis and loss of muscle may
all meet criteria for obesity treatment yet their needs are very different.
The reproductive years
For younger women living with obesity, insulin resistance and PMOS,
improving metabolic health can have consequences extending well
beyond weight loss.
Insulin resistance is an important part of the picture for many women
with PMOS. Improving metabolic health may also affect menstrual
regularity, ovulation and fertility. This creates an obvious need
to talk about pregnancy intentions and contraception when prescribing,
because GLP-1 medications should not be used during pregnancy but
I think the conversation needs to go further than that.
We should know something about the woman’s wider health. Does she
have painful or heavy periods? Endometriosis? PMDD? Has she had
gestational diabetes? What is her relationship with food? Does she
exercise? How does she sleep? What is happening with stress, alcohol
and her mental wellbeing?
These things matter in their own right, but they also influence the
lifestyle changes we may be asking her to make.
Someone living with endometriosis and chronic pelvic pain may find
exercise difficult. A woman with PMDD may experience very different
eating behaviours, sleep and mood at different points in her cycle.
Poor sleep changes appetite and food choices. Stress can drive
emotional eating or alcohol use.
This is why women’s health and Lifestyle Medicine fit together so
naturally. Health behaviours do not happen independently of biology
or the circumstances of someone’s life.
Midlife changes the conversation again
Perimenopause can bring changes in sleep, mood, body composition and
fat distribution, sometimes at exactly the time when work, caring
responsibilities and other pressures are at their greatest.
Cardiometabolic risk becomes increasingly important. So do bone and muscle.
This is the point at which simply telling a woman that she needs
to lose weight becomes particularly inadequate.
Yes, weight may matter. But so do strength, fitness, nutrition, blood
pressure, lipids, glucose regulation, sleep, alcohol, smoking, stress
and social connection and if we are helping a woman lose a substantial
amount of weight, we should probably be asking another question too.
“What exactly is she losing?”
We still remain remarkably fixated on the number on the scales.
A woman loses 15 kg and everyone is delighted but weight loss is
not synonymous with fat loss.
Some loss of lean tissue accompanies substantial weight loss. That
matters at any age, but particularly as women move through midlife
and beyond, when preserving muscle, bone and physical function
becomes increasingly important.
A lighter woman who is considerably weaker is not necessarily
the success story the scales suggest.
Our definition of successful weight management therefore needs to
be broader. We should care about body composition, strength and
physical function as well as kilograms.
Resistance exercise needs to be part of the conversation from the
beginning, not something we remember after the weight has been lost.
Adequate protein matters. Overall dietary quality matters. Bone
health matters but so does being able to get off the floor, carry
shopping, climb stairs and remain physically independent in later life.
When I talk to women about muscle, I am not thinking about the
next six months. I am thinking about the next twenty years.
Eating less isn’t enough
One of the most striking effects of GLP-1 medications is the reduction
in appetite and, for many people, the disappearance of what they
describe as “food noise”.
For someone who has spent decades thinking about food, that can
feel enormously liberating but not feeling hungry is not the same
as not needing nourishment.
I increasingly hear people delightedly reporting that they can
barely eat. That isn’t the objective.
When appetite falls dramatically, protein intake can fall with it.
So can fibre, fruit and vegetables and overall micronutrient intake.
Gastrointestinal side effects can narrow food choices even further.
It is entirely possible to lose a lot of weight while eating a
very poor diet.
We cannot starve ourselves to health.
This is where the nutrition pillar of Lifestyle Medicine becomes
much more interesting than simply creating a calorie deficit.
If medication makes it easier to eat less, we have an opportunity
to help people eat better: enough protein, plenty of fibre, a good
variety of plants and predominantly minimally processed foods.
We can use the period when hunger is quieter to help someone
develop a different relationship with food rather than simply
seeing how little she can eat.
That will matter enormously when doses are reduced or treatment
eventually stops.
We also need to ask how people are eating
There is another aspect of GLP-1 prescribing that deserves more attention.
What happens when someone who already has a difficult relationship
with food discovers a medication that makes it remarkably easy not to eat?
We should be asking about emotional eating, binge eating, restrictive
behaviour, fear of weight gain and previous eating disorders and
we need to keep asking as treatment progresses.
For many people, reducing relentless hunger and food preoccupation
may be profoundly helpful but weight loss alone cannot tell us
whether someone’s relationship with food is becoming healthier.
If a person becomes frightened of eating, increasingly restrictive
or preoccupied with achieving an ever-lower weight, that matters
even if the number on the scales looks impressive.
Psychological health and eating behaviour belong in weight management
just as much as calories and protein do.
This is where the six pillars really earn their place
There is sometimes a sense that effective obesity medication and
Lifestyle Medicine occupy opposite camps. I have never understood why.
If anything, GLP-1 medications make Lifestyle Medicine more important.
Nutrition is only one part of it.
Physical activity, particularly resistance exercise, helps protect
strength and function while weight is being lost.
Restorative sleep matters for metabolic health, appetite, mood and
our ability to make good decisions, and sleep disturbance is already
a major issue for many women during perimenopause and menopause.
Stress matters because it influences sleep, eating behaviour, alcohol
use and motivation.
Avoidance of harmful substances matters. Alcohol is surprisingly easy
to ignore in conversations about weight despite its effects on sleep,
food choices, metabolic health and general wellbeing.
Let’s not forget social connection- this may be the pillar we
underestimate most. People tend to change behaviour more successfully
when they feel supported. Movement is easier to sustain when it is
enjoyable. Eating patterns are shaped by families, workplaces and
culture. Loneliness and isolation affect health in ways that extend
far beyond food.
These things interact. They always have.
The difference with GLP-1 treatment is that, for some people, the
biological drive to eat becomes quieter. That can create a valuable
window in which other changes suddenly feel achievable.
We can and should use that window to build muscle. Improve fitness.
Eat better. Sleep better. Address alcohol. Understand emotional eating.
Find forms of movement that are enjoyable enough to continue. Build
habits and relationships that support health.
That seems to me a far more ambitious objective than simply becoming lighter.
Meanwhile, the internet has joined the consultation
We also need to acknowledge where people are getting their information
about these medications.
Quite often, it isn’t from us.
GLP-1s are discussed constantly on TikTok, Facebook, Reddit and online
forums. People exchange information about doses, side effects,
“microdosing”, combining treatments and where to buy them. Prescription
medicines can start to feel more like consumer products.
There is also a growing market for drugs that have not completed the
regulatory process, including retatrutide.
Anecdote travels incredibly quickly online. “I tried this and it was
amazing” is compelling. Discussions about clinical trials, regulation
and long-term safety are considerably less exciting.
We need to understand that world because our patients are already
living in it and shaming people for buying medication online or
experimenting with it is unlikely to make them more willing to tell us.
I have changed the way I ask the question.
Rather than:
“Are you taking a GLP-1?”
I prefer:
“Have you ever taken a GLP-1 medication?”
It sounds like a tiny distinction, but it can produce a very different answer.
Someone may have taken it last month. They may use it intermittently.
They may be “microdosing”. They may have bought it online. They may
be using something they do not consider worth mentioning because
another clinician did not prescribe it. They may be a bit embarrassed
to admit they are using GLP1 at all.
We need to know – and we need to be kind about how we ask.
Looking beyond the scales
GLP-1 medications are among the most exciting developments in metabolic
medicine for decades. We finally have pharmacological tools capable
of helping some people overcome powerful biological drivers of obesity.
That should be welcomed but medication cannot lift weights for us.
It cannot make our diet nutritionally adequate, restore our sleep,
manage our stress, create meaningful relationships or decide how much
alcohol we drink and it cannot understand the particular circumstances
of the woman sitting in front of us.
Women’s health changes across the life course. Hormones change.
Fertility changes. Body composition changes. Cardiovascular and bone
health become increasingly important. The need to preserve muscle
increases. Our responsibilities, relationships and pressures change too.
Conditions such as PMOS, endometriosis and PMDD are another reminder
that women’s health cannot be separated neatly into reproductive
health, mental health, metabolic health and lifestyle. One affects another.
Good GLP-1 care therefore needs to be about considerably more than
eligibility, dose escalation and kilograms lost.
We need to ask what health looks like for this particular woman,
at this particular point in her life.
That brings us straight back to Lifestyle Medicine: nutrition,
movement, restorative sleep, stress management, healthy relationships
and reducing harmful substances, alongside appropriate evidence-based
medical treatment.
The six pillars have not been made redundant by GLP-1 medications.
Quite the opposite.
The challenge now is not simply to help women lose weight.
It is to use the opportunity these medications give us to help women
build health.
